MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits

MPR Drug News

Humalog KwikPen Approved in New Strength

The Food and Drug Administration (FDA) has approved Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL [U-200]; Eli Lilly) to improve glycemic control in patients with type 1 and type 2 diabetes.

Alzheimer's Drug Won't Be Discontinued After All

Actavis announced that it will continue to distribute Namenda (memantine HCI) tablets due to a recent decision by a panel of the U.S. Court of Appeals for the Second Circuit.

Low Doses of CO May Lessen Brain Damage Post-Hemorrhage

Results from a new study suggest that small controlled doses of carbon monoxide may protect the brain from damage after a subarachnoid hemorrhage by speeding up the clearance of heme that accumulates.

Vaccine to Treat Hypertension in the Works

Researchers have created a DNA vaccine that may help reduce blood pressure for up to six months, new research published in the journal Hypertension has shown.

Results Announced From Phase 3 Trial of Combo COPD Therapy

Novartis announced results from its Phase 3 EXPEDITION trial for indacaterol/glycopyrronium (QVA149) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).